Posts tagged ASCEND-8
Efficacy and safety of ceritinib 450 mg-fed vs 750 mg-fasted in Asian patients (pts) with ALK+ non-small cell lung cancer (NSCLC) in the ASCEND-8 trial
Efficacy and safety of ceritinib 450 mg-fed vs 750 mg-fasted in Asian patients (pts) with ALK+ non-small cell lung cancer (NSCLC) in the ASCEND-8 trial

Asian pts with ALK+ advanced/metastatic NSCLC treated with ceritinib 450 mg-fed showed numerically higher efficacy and less GI toxicity compared to 750 mg-fasted pts. READ ARTICLE

ESMO (European Society for Medical Oncology) Abstract DOI: 10.1016/j.annonc.2020.08.1662

Authors: B.C. Chul Cho, D-W. Kim, U. Batra, K. Park, S-W. Kim, C.T. Yang, V. Pie Jye, V. Sriuranpong, K.G. Babu, K. Amin, Y. Wang, L. Wang, M. Bhering, S. Lucien Geater

Read More
Clinical TrialsKirk SmithASCEND-8, ceritinib